Intervention not reported
Adverse events · adults and children with focal seizures
1 finding from 1 review
Intervention not reported
Adverse events · adults and children with focal seizures
1 finding from 1 review
Intervention not reported
Adverse events · adults and children with generalised tonic‐clonic seizures with or without other seizure types
1 finding from 1 review
Adverse events · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with hepatocellular carcinoma
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events Analysis 11.2 · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · patients with rheumatoid arthritis
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
1 finding from 1 review
Non‐serious adverse events (hyperbilirubinaemia: most frequent) · people with hepatocellular carcinoma
1 finding from 1 review
Secondary outcome: all adverse events · adult patients with the common cold
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary outcome: all adverse events · adult patients with the common cold
1 finding from 1 review
Secondary outcome: all adverse events · adult patients with the common cold
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse events compared with placebo (low certainty).
1 finding from 1 review
Secondary outcome: all adverse eventsOral · adult patients with the common cold
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse eventsOral compared with placebo (low certainty).
1 finding from 1 review
Secondary outcome: all adverse eventsTopical · adult patients with the common cold
1 finding from 1 review
Intervention not reported
Adverse events: a. hypoglycaemia (% of participants)
1 finding from 1 review
Intervention not reported
Adverse events: a. mild hypoglycaemia (% of participants)
1 finding from 1 review
Intervention not reported
Adverse events: a. mild hypoglycaemia (episodes per participant)
1 finding from 1 review